|
WO2016123071A1
|
|
Methods of identifying essential protein domains
|
|
WO2016081769A1
|
|
Lasertag: a toolkit allowing the space-specific recovery, control and modification of single cells and biological molecules in vivo
|
|
WO2014145613A2
|
|
Transposon activation during aging and neuronal decline
|
|
US2014200244A1
|
|
Phenylethanolamine-based NMDA receptor antagonists
|
|
EP2922960A1
|
|
Mutations in solanaceae plants that modulate shoot architecture and enhance yield-related phenotypes
|
|
WO2013169749A1
|
|
Phosphatidylinositol monophosphate levels as disease prognosticators
|
|
US2014297199A1
|
|
Drug screening method and uses thereof
|
|
WO2012178122A2
|
|
Phenocopy model of disease
|
|
US7947653B1
|
|
Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
|
|
WO2011072205A2
|
|
Genetic markers indicative of a cancer patient response to trastuzumab (herceptin)
|
|
WO2010126590A1
|
|
Ptp1b inhibitors
|
|
WO2010111712A2
|
|
Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
|
|
WO2010096696A2
|
|
Harnessing high throughput sequencing for multiplexed specimen analysis
|
|
WO2010085343A1
|
|
Methods and arrays for profiling dna methylation
|
|
US2010273660A1
|
|
ONCOGENOMICS-BASED RNAi SCREEN AND USE THEREOF TO IDENTIFY NOVEL TUMOR SUPPRESSORS
|
|
US2009226459A1
|
|
Role of fgf-19 in cancer diagnosis and treatment
|
|
US2009286242A1
|
|
MicroRNA Expression Profiling and Uses Thereof
|
|
WO2009055724A2
|
|
High throughput methods for functionally determining rna interference efficiency
|
|
WO2009042798A1
|
|
Methods for treating fibrosis by modulating cellular senescence
|
|
WO2009037633A2
|
|
Method for the analysis of ovarian cancer disorders
|
